 2. Patients must have one of the following: somatic mutations or deletions in BRCA1 or BRCA2; genomic alterations in other BRCA pathway genes subcohorts: a. ATM, b. PALB2, c. Fanconi Anemia genes, d. ARID1A, and e. other genes, e.g. MER11, RAD50, NBS1, ATR; amplification of EMSY; mutations or homozygous deletions in PTEN andor PTEN loss by IHC; homologous recombination deficiency Myriad HRD score 42; not breast or ovarian cancer; or germline mutation in BRCA1 or BRCA 2 not breast or ovarian cancer 